Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Farxiga

- PMLiVE

AstraZeneca’s Farxiga shows benefits for heart failure patients in phase 3 trial

The SGLT2 inhibitor improved symptom burden, physical limitations and quality of life

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

AstraZeneca and Medera’s Novoheart develop first human models of heart failure

The ‘heart-in-a-jar’ model will be used to effectively test drug candidates for HFpEF patient

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

Medscape Education: Key Takeaways from Tapas and Trends

This year at ESC, Medscape Education Global gathered with conference attendees and leading KOLs for an education event at the Gaudi House in Barcelona where they examined the new data...

Medscape Education Global

Medscape Education #ESC Tapas and Trends Full Panel Discussion

This year at ESC, Medscape Education Global gathered with conference attendees and leading KOLs for an education event at the Gaudi House in Barcelona where they examined the new data...

Medscape Education Global

- PMLiVE

A Look at What’s Next After ESC

This year at ESC, Medscape Education Global gathered with conference attendees and leading KOLs for an education event at the Gaudi House in Barcelona where they examined the new data...

Medscape Education Global

- PMLiVE

FDA approves scPharmaceuticals’ on-body infusor for congestive heart failure

The at-home device delivers the equivalent of what a patient would receive by way of IV

- PMLiVE

A powerful care platform connects medical professionals and patients

Education platforms that disseminate the latest advances in cardiovascular medicine to cardiologists, physicians and healthcare professionals are helping deliver better outcomes for heart patients.

Medscape Education Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links